Arcadia Biosciences Completes Full Acquisition of Specialty Products Unit

TL;DR

Arcadia Biosciences just bought out its partner's stake in Arcadia Specialty Products, now owning 100%.

AI Summary

Arcadia Biosciences, Inc. announced on May 13, 2024, the completion of its acquisition of the remaining 50% interest in Arcadia Specialty Products, LLC from its joint venture partner, for an undisclosed amount. This transaction consolidates full ownership of Arcadia Specialty Products under Arcadia Biosciences, Inc. The company also reported on the entry into a material definitive agreement and the completion of an asset disposition.

Why It Matters

This move consolidates full ownership of a key business unit, potentially streamlining operations and strategic decision-making for Arcadia Biosciences.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement and asset disposition, suggesting significant corporate activity that could carry inherent risks.

Key Players & Entities

• Arcadia Biosciences, Inc. (company) — Registrant
• Arcadia Specialty Products, LLC (company) — Acquired entity
• May 13, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $4,000,000 — rchased Assets, Pioneer paid to Arcadia $4,000,000 in cash, which consideration was determ

Filing Documents

• rkda-20240513.htm (8-K) — 43KB
• rkda-ex10_1.htm (EX-10.1) — 487KB
• 0000950170-24-061526.txt ( ) — 689KB
• rkda-20240513.xsd (EX-101.SCH) — 24KB
• rkda-20240513_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On May 13, 2024, Arcadia Biosciences, Inc. ("Arcadia") entered into an Asset Purchase Agreement (the "Agreement") with Pioneer Hi-Bred International, Inc. ("Pioneer"), an indirect, wholly-owned subsidiary of Corteva, Inc., pursuant to which on May 13, 2024 Arcadia sold or licensed to Pioneer certain patent and related rights associated with Arcadia's resistant starch durum wheat trait ("Purchased Assets"). Since 2017, Pioneer has worked to introgress the resistant starch durum wheat trait into elite germplasm lines. As consideration for the sale and license of Purchased Assets, Pioneer paid to Arcadia $4,000,000 in cash, which consideration was determined based on negotiations between the parties. The Agreement includes a number customary provisions addressing matters such as closing deliverables, representations and warranties, covenants, survival of the representations and warranties for a period of time after the closing, and indemnification obligations. The preceding description of the Agreement does not purport to be complete, and is qualified in its entirety by reference to the Agreement, which is filed as an Exhibit to this Current Report on Form 8-K. The representations, warranties and covenants contained in the Agreement have been made solely for the benefit of the parties to the Agreement and: (i) may be intended not as statements of fact but rather as a way of allocating risk among the parties if those statements prove to be inaccurate; and (ii) were made only as of the date of the Agreement or such other dates as may be specified in the Agreement and are subject to more recent developments. Accordingly, any such representations and warranties should not be relied upon as characterizations of the actual state of facts or affairs on the date they were made or at any other time.

01 Completion of Acquisition or Disposition of Assets

Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 2.01. The Purchased Assets never have been recorded on the balance sheets included in Arcadia's periodic filings with the SEC.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1*+ Asset Purchase Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Non-material schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby undertakes to furnish supplementally copies of any of the omitted schedules and exhibits upon request by the SEC. + Certain marked information has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCADIA BIOSCIENCES, INC. Date: May 17, 2024 By: /s/ THOMAS J. SCHAEFER Thomas J. Schaefer, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR